aci-gastro_-_Edited.png

Wednesday, Sept. 9, 2026 | 1–5 p.m. ET
Live via Zoom Webinar

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for gastrointestinal cancers. FREE for healthcare professionals, students, patients and patient advocates.

New for 2026

  • Presentation dedicated completely to toxicity management, addressing best practices and sharing practical experience when managing adverse events in patients receiving immunotherapies for GI cancers.
  • Compare the pros and cons associated with subcutaneous vs. intraveneous delivery of ICIs.
The 2026 SITC Advances in Cancer Immunotherapy Series is supported, in part, through medical education grants from
AstraZeneca Pharmaceuticals, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation. 

Program Organizers

Sukeshi Arora, MD

Sukeshi Arora, MD
UT Health San Antonio

Dung Le, MD

Dung Le, MD
Johns Hopkins University School of Medicine

Zev Wainberg, MD

Zev Wainberg, MD
University of California
Los Angeles

Program Agenda

1–1:05 p.m.

 

Welcome

1:05–1:35 p.m.

 
Upper GI/Gastric/Gastroesophageal Cancers

1:35–2:05 p.m.

  
Colorectal cancer (rectal cancer, immunotherapy in MSH vs MSS CRC)

2:05–2:35 p.m.

 
HCC and Hepatobiliary Cancer 

2:35–3:05 p.m.

 
Practical Management of Toxicities

3:05–3:20 p.m.

 

Break

3:20–3:40 p.m.

 
Cancer Immunotherapy in Practice – Pharmacy perspectives on Biosimilars

3:40–4 p.m.

 
Cancer Immunotherapy in Practice – Pharmacy or Nursing Perspectives on Subcutaneous vs. Intravenous Immune Checkpoint Inhibitors

4–5 p.m.

 

Faculty Panel

5 p.m.

 

Closing Remarks

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2026 ACI series.

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to onlineeducation@sitcancer.org.

Program Learning Objectives

  • Identify the cancer immunotherapy approaches in use for the treatment of gastrointestinal cancers, including microsatellite instability-high and mismatch repair deficient tumors.

  • Summarize recent updates in cancer immunotherapy for gastrointestinal cancers including emerging toxicities and management.

  • Implement cancer immunotherapy for gastrointestinal cancer into clinical practice appropriately.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and the Society for Immunotherapy of Cancer (SITC). Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

Successful ABIM_Logo.jpgcompletion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

Partners designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Partners designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Disclosure of Conflicts of Interest

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

The 2026 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Advanced Practitioner Society for Hematology and Oncology and the Association of Cancer Care Centers.

Partners for Advancing Clinical Education Logo

The 2026 ACI series is jointly provided by Partners for Advancing Clinical Education (Partners) and the Society for Immunotherapy of Cancer.